Rifaximin Protects Against Inflammation and Fibrosis in MASH: Any Role for Ethanol-Producing Bacteria?

Mohamed Abouelkheir, Dalia A Shabaan, Ahmed E Taha

Abstract read

In one paragraph

Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mohamed AbouelkheirDepartment of Pharmacology and Therapeutics, College of Medicine, Jouf University, Sakaka City 72388, Saudi Arabia.

Dalia A ShabaanDepartment of Medical Histology and Cell Biology, Faculty of Medicine, Mansoura University, Mansoura City 35516, Egypt.ORCID 0000-0003-0121-3211

Ahmed E TahaMicrobiology and Immunology Unit, Department of Pathology, College of Medicine, Jouf University, Sakaka City 72388, Saudi Arabia.ORCID 0000-0002-5766-4495

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic Dysfunction-Associated Steato-Hepatitis (MASH) is a multiple-hit disease. Endotoxins, ethanol, and other metabolites of certain gut microbiota can reach the liver and accelerate inflammation and disease progression. Targeting ethanol-producing colonic bacteria with rifaximin could affect the progress of MASH. In the present study, thirty mice were assigned to three groups (

Indexed as

BacteriaEthanolFatty LiverInflammationLiver CirrhosisRifamycinsRifaximinAnimalsCytokinesDisease Models, AnimalLiverMaleMiceCytokinesEthanolRifamycinsRifaximinantimicrobial resistanceE. coliethanolgut microbiotaK. pneumoniaMASLD

Identifiers

PMID41754423

DOI10.3390/pathogens15020170

PMCPMC12943380

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.